In 2018, Spirit achieved a major milestone by selling its first API product in the U.S. market. That same year, the company expanded its capabilities by establishing a dedicated R&D facility in India to develop finished solid oral dosage forms.
In 2018, Spirit achieved a major milestone by selling its first API product in the U.S. market. That same year, the company expanded its capabilities by establishing a dedicated R&D facility in India to develop finished solid oral dosage forms.